Footnote or forecast?
White House report calls for public-partnership to fix drug R&D
The President's Council on Advisors on Science and Technology (PCAST) spent a year working on a report titled Propelling Innovation in Drug Discovery, Development, and Evaluation, and now the authors are trying to ensure it doesn't become just a footnote in future blue ribbon reports.
According to the blue ribbon panel, the best way to fill the gaps identified by PCAST's report - the need for more and better translational research, improving clinical trial capabilities and clarifying regulatory pathways - is to create a high-level Partnership to Accelerate Therapeutics Innovation.
According to PCAST, the partnership should include leaders from the biopharma industry; the academic biomedical research and ethics community; physician societies and pharmacists; patient-focused research foundations